menu
    • menu
    [{"orgOrder":0,"company":"Bio Usawa","sponsor":"Bioeq IP AG","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bio Usawa","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Usawa \/ Bio Usawa","highestDevelopmentStatusID":"15","companyTruncated":"Bio Usawa \/ Bio Usawa"},{"orgOrder":0,"company":"Bio Usawa","sponsor":"DEK Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bio Usawa","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Usawa \/ DEK Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Bio Usawa \/ DEK Vaccines"}]

    Find Clinical Drug Pipeline Developments & Deals by Bio Usawa

    Menu

    Bio Usawa

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bio Usawa

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Bio Usawa

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : DEK Vaccines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bio Usawa Partners with DEK Vaccines to Expand Biopharma Access in Ghana & West Africa

                            Details : Bio Usawa partners with DEK Vaccines to distribute BioUcenta, a ranibizumab biosimilar for diabetic macular edema, across Ghana and West Africa, aiming to improve access to affordable eye care.

                            Product Name : BioUcenta

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 28, 2025

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : DEK Vaccines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bio Usawa

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Bio Usawa

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : Bioeq IP AG

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bio Usawa and Bioeq Partner to Provide Access to Vision-Saving Medicine

                            Details : The partnership grants Bio Usawa exclusive rights to register and commercialize Bioeq’s ranibizumab biosimilar, a monoclonal antibody, under the brand name BioUcenta.

                            Product Name : BioUcenta

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : Bioeq IP AG

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth